AGARWALEYE - Dr Agarwal's Hea
📢 Recent Corporate Announcements
Dr. Agarwal's Health Care Limited has allotted 1,50,282 equity shares of ₹ 1 each to eligible employees following the exercise of options under the ESOP Scheme 2022. This allotment has increased the company's paid-up equity share capital from ₹ 31.68 crore to ₹ 31.69 crore. The shares were issued at three different exercise prices: ₹ 84.93, ₹ 129.88, and ₹ 135.00. The dilution resulting from this allotment is minimal, representing approximately 0.047% of the total share capital.
- Allotment of 1,50,282 equity shares of face value ₹ 1 each to employees.
- Total paid-up equity capital increased from 31,68,07,506 to 31,69,57,788 shares.
- Exercise prices for the tranches were set at ₹ 84.93, ₹ 129.88, and ₹ 135.00 per share.
- The new shares rank pari passu with existing equity shares of the company.
Dr. Agarwal's Health Care Limited has announced that Idearx Services Private Limited is no longer an associate company as of March 30, 2026. This follows an amendment to the Shareholders’ Agreement and Articles of Association which terminated specific governance rights. Despite this change in status, the company retains its 14.54% equity stake in Idearx. The transition means Idearx will no longer be equity-accounted as an associate in the consolidated financial statements.
- Idearx Services Private Limited ceases to be an 'Associate' effective March 30, 2026.
- Dr. Agarwal's Health Care Limited maintains its 14.54% equity stake in Idearx.
- The change follows amendments to the Shareholders’ Agreement and Articles of Association.
- Termination of specific rights under the SHA led to the reclassification of the investment.
Dr. Agarwal's Health Care Limited has announced the closure of its trading window effective March 31, 2026. This action is taken in accordance with SEBI (Prohibition of Insider Trading) Regulations for the finalization of the company's audited financial results for the fiscal year ending March 31, 2026. The restriction applies to all designated persons and their immediate relatives. The trading window will remain closed until 48 hours after the financial results are officially declared to the exchanges.
- Trading window closure starts from March 31, 2026, for all designated persons.
- Closure is linked to the finalization of audited standalone and consolidated financial results for FY 2025-26.
- The window will reopen 48 hours after the board meeting and subsequent results announcement.
- Compliance is maintained under SEBI (Prohibition of Insider Trading) Regulations, 2015.
ICRA Limited has reaffirmed the long-term credit rating of 'ICRA AA- (Stable)' for Dr. Agarwal's Health Care Limited's debt facilities. The rating covers ₹73.80 crores in outstanding long-term loans and ₹126.20 crores in unallocated limits. Additionally, a short-term rating of 'ICRA A1+' was assigned/reaffirmed for the enhanced unallocated amount. This high-grade rating reflects the company's strong creditworthiness and stable financial outlook.
- ICRA reaffirmed 'ICRA AA- (Stable)' rating for ₹73.80 crores in long-term bank loans from HDFC, YES, and ICICI Bank
- Assigned and reaffirmed 'ICRA AA- (Stable)' and 'ICRA A1+' ratings for ₹126.20 crores of unallocated limits
- Total bank facilities covered under the rating action amount to ₹200 crores
- The 'Stable' outlook indicates expected steady operational performance and financial stability
Dr. Agarwal's Health Care Limited (AHCL) has received 'no objection' from NSE and 'no adverse observations' from BSE for its proposed merger with Dr. Agarwal's Eye Hospital Limited (AEHL). This regulatory clearance, following the board's August 2025 approval, allows the company to proceed with filing the scheme before the National Company Law Tribunal (NCLT). The company must now provide detailed disclosures to shareholders, including a cost-benefit analysis and a 3-year financial track record of both entities. The observation letters are valid for six months, requiring the NCLT filing to be completed by August 2026.
- Received 'No Objection' from NSE on Feb 16, 2026, and 'No Adverse Observations' from BSE on Feb 17, 2026
- The scheme involves the amalgamation of Dr. Agarwal's Eye Hospital Limited (AEHL) into Dr. Agarwal's Health Care Limited (AHCL)
- Observation letters are valid for 6 months, setting a deadline for NCLT filing by August 2026
- SEBI mandates disclosure of 3-year Revenue, PAT, and EBITDA for both entities in the explanatory statement to shareholders
- Company required to justify the rationale for the merger occurring shortly after the listing of AHCL
Dr. Agarwal's Health Care Limited (AGARWALEYE) has announced its participation in the 'Chasing Growth 2026' conference organized by Kotak Institutional Equities. The event is scheduled for February 23 and 24, 2026, in Mumbai. The company will engage in physical group and one-on-one meetings with institutional investors. Management has clarified that no unpublished price-sensitive information (UPSI) will be shared during these interactions.
- Participation in the Kotak Institutional Equities – Chasing Growth 2026 conference.
- Meetings scheduled for February 23 and 24, 2026, in Mumbai.
- Format includes both physical group sessions and one-on-one investor interactions.
- Company confirms adherence to Fair Disclosure codes regarding price-sensitive information.
Dr. Agarwal's Health Care reported a robust Q3 FY26 with revenue from operations growing 23% YoY to ₹530 crore. Net profit for the quarter surged 55% YoY to ₹44 crore, driven by a higher mix of complex surgeries and improved operational efficiencies. The company expanded its network to 253 facilities, adding 14 new centers in Q3 alone, with plans to add 16 more in Q4. EBITDA margins remained strong at 28.4%, supported by a 25% increase in daily patient walk-ins to approximately 10,000.
- Q3 FY26 PAT grew 55% YoY to ₹44 crore with margins expanding by 171 bps to 8.1%
- Total network expanded to 253 facilities across 148 cities, with 14 new centers added in Q3 FY26
- Robotic cataract surgeries (Femto) saw a massive 83% YoY growth, reflecting a shift toward high-value procedures
- 9M FY26 EBITDA stood at ₹440 crore, up 23.6% YoY with a healthy margin of 28.4%
- Surgical services remain the primary revenue driver, contributing 67% to the total group revenue
Dr. Agarwal's Health Care Limited has made the audio recording of its earnings conference call available to the public. The call, held on February 04, 2026, discussed the company's unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. This is a standard regulatory filing under SEBI (LODR) Regulations to ensure transparency for all shareholders. Investors can access the recording via the link provided on the company's official website.
- Earnings conference call held on February 04, 2026, following Q3 FY26 results.
- Audio recording link published on the company's website for public access.
- Covers financial performance for the nine-month period ending December 31, 2025.
- Compliance filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Dr. Agarwal's Health Care reported a strong financial performance for 9M FY2026, with total income growing 20.8% YoY to ₹1,548 crore. Profit After Tax (PAT) saw a significant jump of 74.3% YoY, reaching ₹118 crore, driven by improved margins and operational efficiencies. The company expanded its network to 272 facilities, adding 38 new centers during the first nine months of the fiscal year. With a robust pipeline of 16 more facilities planned for Q4 FY26, the company continues its aggressive expansion strategy across India and international markets.
- Total Income grew 20.8% YoY to ₹1,548 Cr for 9M FY26, with EBITDA margins improving to 28.4%.
- PAT increased by 74.3% YoY to ₹118 Cr, reflecting significant operational leverage.
- Network expanded to 272 facilities across 10 countries, with 38 new additions in the first nine months.
- Surgery volumes increased by 11.6% YoY to 238K+, contributing 67% of total revenue mix.
- Aggressive expansion remains on track with 16 new facilities planned for launch in Q4 FY26.
Dr. Agarwal's Health Care Limited has approved the grant of 4,44,500 stock options to eligible employees under its 2022 ESOP scheme. The options will vest over a four-year period, with 25% vesting annually starting from February 2027. The exercise price will be determined based on the Fair Market Value at the time of the grant, with a potential discount of up to 20%. This move is intended to retain talent and align employee interests with long-term shareholder value.
- Grant of 4,44,500 options convertible into equity shares of face value ₹1 each
- Vesting schedule follows a 4-year staggered approach at 25% per annum
- Exercise price linked to Fair Market Value with a maximum 20% discount allowed
- Options must be exercised within one year from the respective vesting dates
- Approved by the Nomination and Remuneration Committee on February 03, 2026
Dr. Agarwal's Health Care Limited reported a robust financial performance for 9M FY26, with Profit After Tax (PAT) surging 74.3% YoY to ₹118 Crores. Total income grew by 20.8% to ₹1,548 Crores, supported by the addition of 38 new centers, bringing the total network to 272 facilities across 10 countries. The company also announced the incorporation of a new subsidiary in Ethiopia and the cessation of Idearx Services as an associate company, while maintaining a 14.54% equity stake.
- 9M FY26 PAT increased by 74.3% YoY to ₹118 Crores; Q3 FY26 PAT grew 54.5% to ₹44 Crores
- Total Income for 9M FY26 rose 20.8% YoY to ₹1,548 Crores, driven by healthy patient volumes
- Network expanded to 272 facilities with 38 new centers added in the first nine months of FY26
- EBITDA for 9M FY26 grew 23.6% YoY to ₹440 Crores with margins improving to 28.4%
- Performed 238,283 surgeries in 9M FY26, representing an 11.6% growth compared to the previous year
Dr. Agarwal's Health Care reported a robust Q3 FY26 with revenue from operations growing 23% YoY to ₹530 crore, driven by healthy patient volumes and mature facility performance. Profit After Tax (PAT) witnessed a significant jump of 54.5% YoY to ₹44 crore, while 9M FY26 PAT soared 74.3% to ₹118 crore. The company continued its aggressive expansion, adding 14 new centers in Q3 to reach a total network of 272 facilities. Additionally, the board approved a new subsidiary in Ethiopia and the reclassification of Idearx from an associate to a regular investment.
- Q3 FY26 Total Income grew 21.9% YoY to ₹540 crore; 9M FY26 income reached ₹1,548 crore.
- EBITDA for Q3 FY26 increased by 21.3% YoY to ₹155 crore with a healthy margin of 28.6%.
- Surgery volumes rose 11.2% YoY to 81,002 in Q3; total surgeries for 9M FY26 reached 238,283.
- Revenue from mature facilities grew by 37.8% YoY, indicating strong organic growth in established centers.
- Network expanded to 272 facilities across 10 countries, with 38 centers added in the first nine months of FY26.
Dr. Agarwal's Health Care Limited (AGARWALEYE) has scheduled an investor meeting for February 06, 2026. The company will participate in the JM Financial India Xchange conference held physically in Singapore. The engagement will include both group and one-on-one interactions with institutional investors. The company has explicitly stated that no unpublished price-sensitive information (UPSI) or forward-looking statements will be shared during these sessions.
- Investor conference scheduled for February 06, 2026, in Singapore.
- Organized by JM Financial India Xchange involving physical meetings.
- Format includes both group and one-on-one interactions with analysts and investors.
- Disclosure made in compliance with SEBI (LODR) Regulations, 2015.
- Company confirms no unpublished price-sensitive information will be discussed.
Dr. Agarwal's Health Care Limited has scheduled a Board Meeting on February 3, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025. Following the results, the company will host an earnings conference call on February 4, 2026, at 11:30 A.M. IST. The call will feature top management, including the CEO and CFO, providing a platform for analysts and investors to discuss the company's recent performance and future outlook.
- Board meeting scheduled for February 3, 2026, to approve Q3 and 9M FY26 results.
- Earnings conference call set for February 4, 2026, from 11:30 A.M. to 12:30 P.M. IST.
- Trading window remains closed until 48 hours after the financial results announcement.
- Management representation includes CEO Dr. Adil Agarwal and CFO Mr. Yashwanth Venkat.
Dr. Agarwal's Health Care Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by KFin Technologies Limited, confirms that all dematerialization and rematerialization requests for the quarter ended December 31, 2025, have been processed. This is a standard administrative filing required by all listed companies to ensure the integrity of the shareholding records. The filing indicates that the company is in compliance with depository regulations and has updated the stock exchanges accordingly.
- Compliance certificate submitted for the quarter ended December 31, 2025
- Issued by Registrar and Share Transfer Agent (RTA), KFin Technologies Limited
- Confirms adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
- Verification of dematerialized and rematerialized securities completed for BSE and NSE
Financial Performance
Revenue Growth by Segment
Consolidated revenue from operations grew 28.5% YoY to INR 1,711 Cr in FY25. In H1 FY26, revenue reached INR 986 Cr, a 20.1% increase YoY. Mature facilities contributed 74.6% of H1 FY26 revenue, while emerging facilities (less than 3 years old) grew to represent 25.4% of revenue. Surgeries remain the dominant segment, contributing 65% of total FY25 revenues.
Geographic Revenue Split
India operations accounted for 89.8% of revenue in H1 FY26 (INR 885.4 Cr), while international operations (primarily Africa) contributed 10.2% (INR 100.6 Cr). The company has significantly expanded its non-South Indian presence, with 31% of centers located in these markets as of September 2025, up from 16% in March 2022.
Profitability Margins
Gross margins improved to 78.7% in Q2 FY26 from 78.0% in Q2 FY25. Net Profit Margin stood at 7.2% in Q2 FY26, a significant increase from 5.0% in the previous year. The listed subsidiary (AEHL) saw PBT margins move from 18.3% to 21.7% due to cost efficiencies in doctor and employee expenses.
EBITDA Margin
Consolidated EBITDA margin was 28.3% in H1 FY26 (INR 285 Cr), up from 27.3% in H1 FY25. This 100 bps improvement was driven by a 24.9% YoY growth in EBITDA and better absorption of fixed costs in emerging facilities. Operating EBITDA for the subsidiary AEHL reached 35.0% in Q2 FY26.
Capital Expenditure
The company added 24 new facilities in H1 FY26 (13 in Q1 and 11 in Q2), bringing the total center count to 258 as of September 30, 2025, compared to 180 in March 2024. While specific future INR Cr capex is not detailed, the rapid expansion from 180 to 258 centers indicates heavy investment in greenfield and brownfield sites.
Credit Rating & Borrowing
The company maintains a healthy financial risk profile with an interest coverage ratio of 6.04 times in H1 FY26. External borrowings were reduced to INR 246.9 Cr following the February 2025 IPO, down from INR 387.8 Cr in FY24. Total outside liabilities to tangible networth (TOL/TNW) stood at 0.94 times as of September 2025.
Operational Drivers
Raw Materials
Cost of Goods Sold (COGS), which includes surgical lenses, medical consumables, and pharmacy stock, represents 21.3% of total revenue as of Q2 FY26.
Import Sources
Not specifically disclosed in available documents, though the company utilizes advanced global technologies like FEMTO Cataract and SMILE for refractive surgeries.
Capacity Expansion
Current capacity stands at 258 centers as of September 30, 2025. The company expanded from 180 centers in March 2024, representing a 43% increase in facility footprint within 18 months.
Raw Material Costs
COGS grew 14.6% YoY to INR 108 Cr in Q2 FY26, which was lower than the 19.7% revenue growth, leading to gross margin expansion. Procurement strategies focus on increasing the adoption of premium lenses to improve yield per patient.
Manufacturing Efficiency
Surgical volume grew by 8% in Q2 FY26, while value growth contributed 4.8%. Revenue per surgery increased by 9% YoY, driven by a shift toward complex cataracts and premium lens adoption.
Strategic Growth
Expected Growth Rate
20%
Growth Strategy
Growth is driven by a mix of same-store sales growth (exemplified by 42% top-line growth in Telangana) and aggressive network expansion (78 centers added since March 2024). The company targets the shift from unorganized to organized eye care, leveraging its 25% market share in the organized segment and acquiring high-margin clinics like Dr. Thind (40% EBITDA).
Products & Services
Comprehensive eye care services including Cataract surgeries (largest segment), Refractive surgeries (SMILE, FEMTO), and specialized treatments for retinal and corneal diseases.
Brand Portfolio
Dr. Agarwal's Eye Hospital, Dr. Thind Eye Care, Aditya Jyot Eye Hospital.
New Products/Services
Increased adoption of premium intraocular lenses and advanced refractive technologies (SMILE/FEMTO) are expected to continue driving the 4.8% value growth component of revenue.
Market Expansion
Expansion is focused on non-South Indian markets, which now comprise 31% of the network. Recent growth includes 4 new facilities in Telangana and entry into North Indian markets.
Market Share & Ranking
Estimated 25% market share of the organized eye care segment in India.
Strategic Alliances
The group consolidates several entities including Orbit Healthcare Services (Mauritius), Elisar Life Science, and Aditya Jyot Eye Hospital.
External Factors
Industry Trends
The industry is seeing a structural shift from unorganized standalone clinics to organized chains. Consumer preference is moving toward advanced surgical techniques and premium lenses, supporting a 38% revenue CAGR for the company from FY21-25.
Competitive Landscape
Key competition arises from other corporate hospital chains and a high density of single-doctor standalone clinics which may offer lower pricing.
Competitive Moat
The moat is built on a strong brand recall, a large pool of 881 doctors, and a 25% share of the organized market. This is sustained by providing doctors with state-of-the-art technology and incentives that exceed individual practice benefits, creating high switching costs for medical talent.
Macro Economic Sensitivity
Revenue growth in Q2 FY26 was slightly tempered by unseasonal rains in core markets and festival timing, though the company still achieved 19.8% growth in India.
Consumer Behavior
Increasing demand for refractive error correction (SMILE/FEMTO) and premium cataract solutions among the aging population and urban consumers.
Geopolitical Risks
Exposure to African markets (10.2% of revenue) introduces regional economic and political risks, though Africa revenue grew 17.4% in H1 FY26.
Regulatory & Governance
Industry Regulations
The group operates in a highly regulated healthcare industry requiring multiple government approvals for facility operations and medical standards. Compliance is monitored by an Audit Committee and independent internal audits.
Taxation Policy Impact
Effective tax rate for Q2 FY26 was approximately 31.5% (INR 17 Cr tax on INR 54 Cr PBT).
Risk Analysis
Key Uncertainties
The primary uncertainty is the ability to attract and retain skilled ophthalmologists in a supply-constrained market; failure to do so would directly impact the 65% revenue contribution from surgeries.
Geographic Concentration Risk
While diversifying, the company still has a high concentration in South India (Tamil Nadu and Telangana), making it sensitive to regional weather patterns (e.g., unseasonal rains) and local competition.
Third Party Dependencies
Dependency on insurance providers and TPAs for 29.6% of revenue, making the company sensitive to changes in reimbursement rates or approval timelines.
Technology Obsolescence Risk
High risk if the company fails to continuously invest in the latest ophthalmic equipment (like FEMTO/SMILE), as technology is a key differentiator against standalone clinics.
Credit & Counterparty Risk
Receivables quality is high with a turnover ratio of 15.53; however, government payors (8.5% of mix) typically have longer payment cycles than cash/insurance segments.